Publicaciones en colaboración con investigadores/as de German Cancer Research Center (8)

2021

  1. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

    British Journal of Haematology, Vol. 194, Núm. 1, pp. 132-139

  2. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

2019

  1. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

    Leukemia, Vol. 33, Núm. 1, pp. 159-170

2018

  1. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials

    Hematological Oncology, Vol. 36, Núm. 2, pp. 463-470

2017

  1. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017

  2. Second primary malignancies in multiple myeloma: An overview and IMWG consensus

    Annals of Oncology, Vol. 28, Núm. 2, pp. 228-245

2015

  1. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Haematologica, Vol. 100, Núm. 10, pp. 1327-1333

  2. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

    Haematologica, Vol. 100, Núm. 10, pp. 1334-1339